Prelude Therapeutics Inc (NASDAQ:PRLD) — Market Cap & Net Worth
Market Cap & Net Worth: Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (NASDAQ:PRLD) has a market capitalization of $140.19 Million ($140.19 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17994 globally and #4158 in its home market, demonstrating a 10.41% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Prelude Therapeutics Inc's stock price $4.35 by its total outstanding shares 43765011 (43.77 Million). Review PRLD current and long-term liabilities to assess the company's total debt and financial obligations.
Prelude Therapeutics Inc Market Cap History: 2020 to 2026
Prelude Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows change from $3.13 Billion to $190.38 Million (-26.91% CAGR).
Index Memberships
Prelude Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.01% | #498 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1758 of 3165 |
Weight: Prelude Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Prelude Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Prelude Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.97x
Prelude Therapeutics Inc's market cap is 7.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $55.80 Million | $7.00 Million | -$127.17 Million | 7.97x | N/A |
Competitor Companies of PRLD by Market Capitalization
Companies near Prelude Therapeutics Inc in the global market cap rankings as of June 19, 2026.
Key companies related to Prelude Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Prelude Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Prelude Therapeutics Inc's market cap moved from $3.13 Billion to $ 190.38 Million, with a yearly change of -26.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $190.38 Million | +50.00% |
| 2025 | $126.92 Million | +127.45% |
| 2024 | $55.80 Million | -70.14% |
| 2023 | $186.88 Million | -29.30% |
| 2022 | $264.34 Million | -51.49% |
| 2021 | $544.87 Million | -82.60% |
| 2020 | $3.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Prelude Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $140.19 Million USD |
| MoneyControl | $140.19 Million USD |
| MarketWatch | $140.19 Million USD |
| marketcap.company | $140.19 Million USD |
| Reuters | $140.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and oral… Read more